Portal de Periódicos da CAPES

Porphyromonas , a potential predictive biomarker of Pseudomonas aeruginosa pulmonary infection in cystic fibrosis

2019; BMJ; Volume: 6; Issue: 1 Linguagem: Inglês

10.1136/bmjresp-2018-000374

2052-4439

Marlène Keravec, Jérôme Mounier, Charles-Antoine Guilloux, Marie-Sarah Fangous, Stanislas Mondot, Sophie Vallet, S. Gouriou, Rozenn Le Berre, G. Rault, Claude Férec, Georges Barbier, Patricia Lepage, Geneviève Héry-Arnaud,

Antibiotic Resistance in Bacteria

Introduction Pseudomonas aeruginosa pulmonary infections are the primary cause of morbi-mortality in patients with cystic fibrosis (CF). In this cohort study, the objective was to identify candidate biomarkers of P. aeruginosa infection within the airway microbiota. Methods A 3-year prospective multicentre study (PYOMUCO study) was conducted in Western France and included patients initially P. aeruginosa free for at least 1 year. A 16S-targeted metagenomics approach was applied on iterative sputum samples of a first set of patients (n=33). The composition of airway microbiota was compared according to their P. aeruginosa status at the end of the follow-up (colonised vs non-colonised), and biomarkers associated with P. aeruginosa were screened. In a second step, the distribution of a candidate biomarker according to the two groups of patients was verified by qPCR on a second set of patients (n=52) coming from the same cohort and its load quantified throughout the follow-up. Results Porphyromonas (mainly P. catoniae ) was found to be an enriched phylotype in patients uninfected by P. aeruginosa (p<0.001). This result was confirmed by quantitative PCR. Conversely, in patients who became P. aeruginosa- positive, P. catoniae significantly decreased before P. aeruginosa acquisition (p=0.014). Discussion Further studies on replication cohorts are needed to validate this potential predictive biomarker, which may be relevant for the follow-up in the early years of patients with CF. The identification of infection candidate biomarkers may offer new strategies for CF precision medicine.